Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

This study has been completed.
National Cancer Institute (NCI)
North Central Cancer Treatment Group
NCIC Clinical Trials Group
NSABP Foundation Inc
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group Identifier:
First received: January 4, 2002
Last updated: March 8, 2012
Last verified: January 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2009
  Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
Wagner LI, Wang M, Miller K, et al.: Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-5078, S239, 2006.
Miller KD, Wang M, Gralow J, et al.: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-3, 2005.